» Articles » PMID: 33537098

Overall Survival of Pancreatic Ductal Adenocarcinoma is Doubled by Deletion in the KPC Mouse

Overview
Journal Theranostics
Date 2021 Feb 4
PMID 33537098
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The activity of aldehyde dehydrogenase 7A1 (ALDH7A1), an enzyme that catalyzes the lipid peroxidation of fatty aldehydes was found to be upregulated in pancreatic ductal adenocarcinoma (PDAC). knockdown significantly reduced tumor formation in PDAC. We raised a question how ALDH7A1 contributes to cancer progression. To answer the question, the role of ALDH7A1 in energy metabolism was investigated by knocking down and knockdown gene in mouse model, because the role of ALDH7A1 has been reported as a catabolic enzyme catalyzing fatty aldehyde from lipid peroxidation to fatty acid. Oxygen consumption rate (OCR), ATP production, mitochondrial membrane potential, proliferation assay and immunoblotting were performed. In study, two human PDAC cell lines were used for pre-clinical xenograft model as well as spontaneous PDAC model of KPC mice was also employed for anti-cancer therapeutic effect. knockdown significantly reduced tumor formation with reduction of OCR and ATP production, which was inversely correlated with increase of 4-hydroxynonenal. This implies that ALDH7A1 is critical to process fatty aldehydes from lipid peroxidation. Overall survival of PDAC is doubled by cross breeding of KPC () and mice. Inhibitions of ALDH7A1 and oxidative phosphorylation using gossypol and phenformin resulted in a regression of tumor formation in xenograft mice model and KPC mice model.

Citing Articles

Identification of Candidate Genes for Sebum Deposition in Pekin Ducks Using Genome-Wide Association Studies.

Lv X, Shi B, Ren H, Yang W, Qu L, Obianwuna U Genes (Basel). 2025; 15(12.

PMID: 39766820 PMC: 11675992. DOI: 10.3390/genes15121553.


A new nano approach to prevent tumor growth in the local treatment of glioblastoma: Temozolomide and rutin-loaded hybrid layered composite nanofiber.

Ercelik M, Tekin C, Gurbuz M, Tuncbilekli Y, Dogan H, Mutlu B Asian J Pharm Sci. 2024; 19(6):100971.

PMID: 39640055 PMC: 11617954. DOI: 10.1016/j.ajps.2024.100971.


Progress in antitumor mechanisms and applications of phenformin (Review).

Zhong Q, Li D, Yang X Oncol Rep. 2024; 52(5).

PMID: 39301645 PMC: 11421015. DOI: 10.3892/or.2024.8810.


Human Aldehyde Dehydrogenases: A Superfamily of Similar Yet Different Proteins Highly Related to Cancer.

Xanthis V, Mantso T, Dimtsi A, Pappa A, Fadouloglou V Cancers (Basel). 2023; 15(17).

PMID: 37686694 PMC: 10650815. DOI: 10.3390/cancers15174419.


Long-Chain Acyl Coenzyme A Dehydrogenase, a Key Player in Metabolic Rewiring/Invasiveness in Experimental Tumors and Human Mesothelioma Cell Lines.

Pouliquen D, Ortone G, Rumiano L, Boissard A, Henry C, Blandin S Cancers (Basel). 2023; 15(11).

PMID: 37297007 PMC: 10252348. DOI: 10.3390/cancers15113044.


References
1.
Saif M . Advancements in the management of pancreatic cancer: 2013. JOP. 2013; 14(2):112-8. DOI: 10.6092/1590-8577/1481. View

2.
Kang J, Lee S, Lee J, Nam B, Seong T, Son J . Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion. Oncotarget. 2016; 7(31):49397-49410. PMC: 5226516. DOI: 10.18632/oncotarget.10354. View

3.
Kang J, Lee S, Hong D, Lee J, Ahn H, Ahn J . Aldehyde dehydrogenase is used by cancer cells for energy metabolism. Exp Mol Med. 2016; 48(11):e272. PMC: 5133370. DOI: 10.1038/emm.2016.103. View

4.
Chen L, Zhou D, Liu Z, Huang X, Liu Q, Kang Y . Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncol Rep. 2018; 39(3):1081-1089. PMC: 5802029. DOI: 10.3892/or.2018.6198. View

5.
Sohal D, Mangu P, Khorana A, Shah M, Philip P, OReilly E . Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34(23):2784-96. PMC: 5019760. DOI: 10.1200/JCO.2016.67.1412. View